J. Worley

Cellular activation of proMMP‐13 by MT1‐MMP depends on the C‐terminal domain of MMP‐13

P. Soloway, G. Murphy, M. Patterson, 2002, FEBS letters.

Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy.

M. Sampson, D. Hughes, I. Davies, 2006, Diabetes research and clinical practice.

Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).

D. Edwards, P. Soloway, G. Murphy, 2003, The Biochemical journal.

Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail.

R. Williamson, G. Murphy, V. Knäuper, 2003, Biochemical Society symposium.

Metalloproteinase Expression in PMA-stimulated THP-1 Cells

M. Sampson, D. Hughes, D. Edwards, 2003, Journal of Biological Chemistry.

Low density lipoprotein from patients with Type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genes

M. Sampson, D. Hughes, N. Dozio, 2007, Cardiovascular diabetology.